1. McKeage K. Indacaterol: a review of its use as maintenance therapy in patients with chronic obstructive pulmonary disease. Drugs. 2012;72(4):543–63.
2. Carter NJ. Inhaled glycopyrronium bromide: a review of its use in patients with moderate to severe chronic obstructive pulmonary disease. Drugs. 2013;73(7):741–53.
3. Novartis. Novartis first-in-class once-daily dual bronchodilator Ultibro Breezhaler (QVA149) achieves near simultaneous approval for COPD patients in Europe and Japan [media release]. 23 Sep 2013. http://www.novartis.com/newsroom/media-releases/en/2013/1730580.shtml .
4. Novartis Pharma K.K. Ultibro inhalation capsules: Japanese prescribing information. 2013. http://product.novartis.co.jp/ult/pi/ULT1309_03.pdf . Accessed 31 Jan 2014.
5. Novartis Europharm Ltd. Ultibro Breezhaler 85 micrograms/43 micrograms, inhalation powder hard capsules: EU summary of product characteristics. 2013. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002679/WC500151255.pdf . Accessed 13 Nov 2013.